<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00475</drugbank-id>
  <drugbank-id>APRD00682</drugbank-id>
  <name>Chlordiazepoxide</name>
  <description>An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.</description>
  <cas-number>58-25-3</cas-number>
  <unii>6RZ6XEZ3CR</unii>
  <average-mass>299.755</average-mass>
  <monoisotopic-mass>299.082539792</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>illicit</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A700</ref-id>
        <pubmed-id>6135616</pubmed-id>
        <citation>Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8.</citation>
      </article>
      <article>
        <ref-id>A701</ref-id>
        <pubmed-id>3089825</pubmed-id>
        <citation>Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42.</citation>
      </article>
      <article>
        <ref-id>A702</ref-id>
        <pubmed-id>458601</pubmed-id>
        <citation>Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50.</citation>
      </article>
      <article>
        <ref-id>A703</ref-id>
        <pubmed-id>851373</pubmed-id>
        <citation>Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89.</citation>
      </article>
      <article>
        <ref-id>A340</ref-id>
        <pubmed-id>6118950</pubmed-id>
        <citation>Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.</synthesis-reference>
  <indication>For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.</indication>
  <pharmacodynamics>Chlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.</pharmacodynamics>
  <mechanism-of-action>Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).</toxicity>
  <metabolism>Hepatic.</metabolism>
  <absorption/>
  <half-life>24-48 hours</half-life>
  <protein-binding/>
  <route-of-elimination>Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.</description>
    <direct-parent>1,4-benzodiazepines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Benzodiazepines</class>
    <subclass>1,4-benzodiazepines</subclass>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>Nitrones</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <substituent>1,4-benzodiazepine</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Amidine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Nitrone</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000632</drugbank-id>
      <name>Chlordiazepoxide hydrochloride</name>
      <unii>MFM6K1XWDK</unii>
      <cas-number>438-41-5</cas-number>
      <inchikey>DMLFJMQTNDSRFU-UHFFFAOYSA-N</inchikey>
      <average-mass>336.22</average-mass>
      <monoisotopic-mass>335.0592175</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide</synonym>
    <synonym language="english" coder="">CDP</synonym>
    <synonym language="english" coder="">Chloradiazepoxide</synonym>
    <synonym language="english" coder="inn/ban/usp">Chlordiazepoxide</synonym>
    <synonym language="latin" coder="inn">Chlordiazepoxidum</synonym>
    <synonym language="english" coder="">Clopoxide</synonym>
    <synonym language="spanish" coder="">Clordiazep√≥xido</synonym>
    <synonym language="english" coder="">Methaminodiazepoxide</synonym>
  </synonyms>
  <products>
    <product>
      <name>Chlorax</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00618454</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide</name>
      <labeller>Direct Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-593</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide</name>
      <labeller>Direct Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-04</started-marketing-on>
      <ended-marketing-on>2016-03-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00522724</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00522988</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00522996</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline HCl</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-265</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072277</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline HCl</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-266</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072278</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-09</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071297</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-09</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071297</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071297</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-0277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071297</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Cap 10mg</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00156590</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide Cap 5mg</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00363596</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>2009-07-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxide Clidinium</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-02</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide HCl</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-0785</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide HCl</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-0786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide HCl</name>
      <labeller>Watson Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0591-0787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-02</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-04</started-marketing-on>
      <ended-marketing-on>2011-12-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-30</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-09</started-marketing-on>
      <ended-marketing-on>2012-02-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-28</started-marketing-on>
      <ended-marketing-on>2014-04-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on>2011-08-12</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-2145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-01</started-marketing-on>
      <ended-marketing-on>2015-05-05</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Contract Pharmacy Services Pa</labeller>
      <ndc-id/>
      <ndc-product-code>67046-909</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Pd Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-061</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-969</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-29</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0622</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-25</started-marketing-on>
      <ended-marketing-on>2018-07-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085461</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-253</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0364</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-15</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>24236-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-20</started-marketing-on>
      <ended-marketing-on>2016-11-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2013-08-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2014-08-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5652</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Contract Pharmacy Services-PA</labeller>
      <ndc-id/>
      <ndc-product-code>67046-910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1752</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Aphena Pharma Solutions - Tennessee, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>71610-263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Clinical Solutions Wholesale, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58118-1590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Clinical Solutions Wholesale, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58118-1033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0158</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085461</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-14</started-marketing-on>
      <ended-marketing-on>2019-11-30</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085461</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-14</started-marketing-on>
      <ended-marketing-on>2019-08-31</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-375</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA083116</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Bi-Coastal Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>42582-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-19</started-marketing-on>
      <ended-marketing-on>2011-12-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-622</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-01</started-marketing-on>
      <ended-marketing-on>2011-02-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-186</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-22</started-marketing-on>
      <ended-marketing-on>2012-12-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Boca Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64376-808</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-19</started-marketing-on>
      <ended-marketing-on>2010-12-20</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-06-20</started-marketing-on>
      <ended-marketing-on>2013-01-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride And Clidinium Bromide</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-03</started-marketing-on>
      <ended-marketing-on>2013-11-04</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-22</started-marketing-on>
      <ended-marketing-on>2012-03-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride And Clidinium Bromide</name>
      <labeller>Acella Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42192-336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-30</started-marketing-on>
      <ended-marketing-on>2016-11-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Marlex Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10135-622</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY</labeller>
      <ndc-id/>
      <ndc-product-code>42582-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Macoven Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>44183-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-04</started-marketing-on>
      <ended-marketing-on>2015-06-04</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Burel Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35573-325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-15</started-marketing-on>
      <ended-marketing-on>2017-03-24</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Cameron Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42494-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-409</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-23</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>Vilvet Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71186-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <labeller>ECI Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>51293-607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-214</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-19</started-marketing-on>
      <ended-marketing-on>2016-03-03</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-14</started-marketing-on>
      <ended-marketing-on>2018-06-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chlordiazepoxyde 25 Cap</name>
      <labeller>Duchesnay Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00448737</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxyde Cap 10mg</name>
      <labeller>Duchesnay Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00430935</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chlordiazepoxyde HCl Cap 25mg</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00434426</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Corax Cap 10mg</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00235873</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Corax Cap 25mg</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00267090</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Corax Cap 5mg</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00295051</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Corium Cap</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00391077</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>2005-04-26</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Librax</name>
      <labeller>Bausch Health US LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-4100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA012750</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Librax</name>
      <labeller>Bausch Health, Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00115630</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1961-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Librium</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3750</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-09-21</started-marketing-on>
      <ended-marketing-on>2014-12-01</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085461</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Librium</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3751</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-09-21</started-marketing-on>
      <ended-marketing-on>2014-12-01</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Librium</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3758</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-09-21</started-marketing-on>
      <ended-marketing-on>2014-12-01</ended-marketing-on>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085475</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Limbitrol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-23</started-marketing-on>
      <ended-marketing-on>2006-12-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA016949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Limbitrol</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-23</started-marketing-on>
      <ended-marketing-on>2009-11-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA016949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Limbitrol DS</name>
      <labeller>Valeant Pharmaceuticals North America</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3806</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-23</started-marketing-on>
      <ended-marketing-on>2008-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA016949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medilium Cap 10 10mg</name>
      <labeller>Medic Laboratory Lt√âe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00134333</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Medilium Cap 5mg</name>
      <labeller>Medic Laboratory Lt√âe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00134325</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-poxide 10mg</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00020923</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-poxide 25mg</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00020931</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-poxide 5mg</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00020915</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2005-08-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-chlorax Capsules USP</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239110</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro Chlorax</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00636223</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Angirex</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Elenium</name>
      <company>Polfa Tarchomin</company>
    </international-brand>
    <international-brand>
      <name>Helogaphen</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Klopoxid</name>
      <company>Nycomed</company>
    </international-brand>
    <international-brand>
      <name>Libritabs</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Multum</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Napoton</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Radepur</name>
      <company>AWD</company>
    </international-brand>
    <international-brand>
      <name>Risolid</name>
      <company>Actavis</company>
    </international-brand>
    <international-brand>
      <name>Silibrin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Sonimen</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Tropium</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Chlordiazepoxide HCl</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide HCl</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide HCl</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Clidinium</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline HCl</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline HCl</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride And Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Librium</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Librium</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Librium</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Limbitrol</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Limbitrol</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Limbitrol DS</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride And Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide and Amitriptyline Hydrochloride</name>
      <ingredients>Amitriptyline + Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride and Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride/Clidinium Bromide</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Librax</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Hydrochloride</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlorax</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Librax</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Medilium Cap 5mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Corax Cap 10mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Corax Cap 25mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Corax Cap 5mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Cap 5mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Corium Cap</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxyde HCl Cap 25mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxyde Cap 10mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxyde 25 Cap</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Pro Chlorax</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
    <mixture>
      <name>Novo-poxide 10mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Chlordiazepoxide Cap 10mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Medilium Cap 10 10mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Novo-poxide 25mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Novo-poxide 5mg</name>
      <ingredients>Chlordiazepoxide</ingredients>
    </mixture>
    <mixture>
      <name>Nu-chlorax Capsules USP</name>
      <ingredients>Chlordiazepoxide + Clidinium</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Coupler Enterprises Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Direct Dispensing Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>H and H Laboratories</name>
      <url>http://www.hhlabs.com</url>
    </packager>
    <packager>
      <name>Heartland Repack Services LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Innoviant Pharmacy Inc.</name>
      <url>http://www.innoviantpharmacy.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Legacy Pharmaceuticals Packaging LLC</name>
      <url>http://www.legacypackaging.com</url>
    </packager>
    <packager>
      <name>Liberty Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Merrell Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Palmetto Pharmaceuticals Inc.</name>
      <url>http://www.palmettopharm.com</url>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>Patheon Inc.</name>
      <url>http://www.patheon.com</url>
    </packager>
    <packager>
      <name>PCA LLC</name>
      <url/>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Pharmedix</name>
      <url>http://www.pharmedixrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Prepackage Specialists</name>
      <url/>
    </packager>
    <packager>
      <name>Prepak Systems Inc.</name>
      <url>http://www.prepaksys.com</url>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Sandhills Packaging Inc.</name>
      <url>http://www.sandhillspackaging.com</url>
    </packager>
    <packager>
      <name>Solco Healthcare US LLC</name>
      <url>http://www.legacypharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>UDL Laboratories</name>
      <url>http://www.udllabs.com</url>
    </packager>
    <packager>
      <name>Va Cmop Dallas</name>
      <url/>
    </packager>
    <packager>
      <name>Valeant Ltd.</name>
      <url>http://www.valeant.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Valeant pharmaceuticals international</manufacturer>
    <manufacturer generic="false" url="">Abbott laboratories pharmaceutical products div</manufacturer>
    <manufacturer generic="false" url="">Rachelle laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Ascot hosp pharmaceuticals inc div travenol laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Barr laboratories inc</manufacturer>
    <manufacturer generic="true" url="">John j ferrante</manufacturer>
    <manufacturer generic="true" url="">Halsey drug co inc</manufacturer>
    <manufacturer generic="true" url="">Impax laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Ivax pharmaceuticals inc sub teva pharmaceuticals usa</manufacturer>
    <manufacturer generic="true" url="">Lederle laboratories div american cyanamid co</manufacturer>
    <manufacturer generic="true" url="">Mm mast and co</manufacturer>
    <manufacturer generic="true" url="">Mylan pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Parke davis div warner lambert co</manufacturer>
    <manufacturer generic="true" url="">Pioneer pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Purepac pharmaceutical co</manufacturer>
    <manufacturer generic="true" url="">Roxane laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Superpharm corp</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Usl pharma inc</manufacturer>
    <manufacturer generic="true" url="">Vangard laboratories inc div midway medical co</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
    <manufacturer generic="true" url="">West ward pharmaceutical corp</manufacturer>
    <manufacturer generic="false" url="">Alra laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Librium 10 mg capsule</description>
      <cost currency="USD">1.61</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Limbitrol DS 10-25 mg tablet</description>
      <cost currency="USD">1.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Librium 25 mg capsule</description>
      <cost currency="USD">2.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Librax capsule</description>
      <cost currency="USD">5.78</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Librax 2.5-5 mg capsule</description>
      <cost currency="USD">6.5</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Chlordiazepoxide 5 mg Capsule</description>
      <cost currency="USD">0.07</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Chlordiazepoxide 10 mg Capsule</description>
      <cost currency="USD">0.11</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Chlordiazepoxide 10 mg capsule</description>
      <cost currency="USD">0.14</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Apo-Chlordiazepoxide 25 mg Capsule</description>
      <cost currency="USD">0.17</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Chlordiazepoxide 5 mg capsule</description>
      <cost currency="USD">0.2</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>ChlordiazePOXIDE HCl 10 mg capsule</description>
      <cost currency="USD">0.31</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>ChlordiazePOXIDE HCl 5 mg capsule</description>
      <cost currency="USD">0.31</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>ChlordiazePOXIDE HCl 25 mg capsule</description>
      <cost currency="USD">0.32</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Chlordiazepoxide 25 mg capsule</description>
      <cost currency="USD">0.72</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Librium 5 mg capsule</description>
      <cost currency="USD">0.84</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Anesthesia</category>
      <mesh-id>D000759</mesh-id>
    </category>
    <category>
      <category>Anti-Anxiety Agents</category>
      <mesh-id>D014151</mesh-id>
    </category>
    <category>
      <category>Benzazepines</category>
      <mesh-id>D001552</mesh-id>
    </category>
    <category>
      <category>Benzodiazepines and benzodiazepine derivatives</category>
      <mesh-id>D001569</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Depressants</category>
      <mesh-id>D002492</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytosine Nucleotides</category>
      <mesh-id>D003597</mesh-id>
    </category>
    <category>
      <category>GABA Agents</category>
      <mesh-id>D018682</mesh-id>
    </category>
    <category>
      <category>GABA Modulators</category>
      <mesh-id>D018757</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Hypnotics and Sedatives</category>
      <mesh-id>D006993</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleotides</category>
      <mesh-id>D009711</mesh-id>
    </category>
    <category>
      <category>Psycholeptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychotropic Drugs</category>
      <mesh-id>D011619</mesh-id>
    </category>
    <category>
      <category>Pyrimidine Nucleotides</category>
      <mesh-id>D011742</mesh-id>
    </category>
    <category>
      <category>Pyrimidines</category>
      <mesh-id>D011743</mesh-id>
    </category>
    <category>
      <category>Ribonucleotides</category>
      <mesh-id>D012265</mesh-id>
    </category>
    <category>
      <category>Tranquilizing Agents</category>
      <mesh-id>D014149</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>25 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N05BA02">
      <level code="N05BA">Benzodiazepine derivatives</level>
      <level code="N05B">ANXIOLYTICS</level>
      <level code="N05">PSYCHOLEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:24.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00475.pdf?1265922738</msds>
  <patents/>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Chlordiazepoxide may increase the sedative activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Chlordiazepoxide may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Chlordiazepoxide may increase the sedative activities of Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Chlordiazepoxide may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>The serum concentration of Chlordiazepoxide can be increased when it is combined with Teduglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Chlordiazepoxide can be increased when it is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sibutramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Dyphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Oxtriphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theobromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Fenethylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 8-azaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01978</drugbank-id>
      <name>7,9-Dimethylguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 7,9-Dimethylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Xanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02245</drugbank-id>
      <name>7-Deazaguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 7-Deazaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02377</drugbank-id>
      <name>Guanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Guanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 9-Methylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Peldesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Hypoxanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 9-Deazaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Propentofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06575</drugbank-id>
      <name>Valomaciclovir</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Valomaciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07954</drugbank-id>
      <name>3-isobutyl-1-methyl-7H-xanthine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08844</drugbank-id>
      <name>Uric acid</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Uric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Doxofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 6-O-benzylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Lisofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Lobucavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Cafedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theodrenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Bamifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Proxyphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Acefylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Etamiphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Pentifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Bufylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Bromotheophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Furafylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with 8-chlorotheophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15122</drugbank-id>
      <name>PCS-499</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with PCS-499.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Aminophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Baclofen is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Amphetamine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of adverse effects can be increased when Enflurane is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of adverse effects can be increased when Butalbital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of adverse effects can be increased when Cabergoline is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The risk or severity of adverse effects can be increased when Topiramate is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of adverse effects can be increased when Clemastine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Atomoxetine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of adverse effects can be increased when Etomidate is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The risk or severity of adverse effects can be increased when Talbutal is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Tolcapone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Cetirizine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of adverse effects can be increased when Trimethadione is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>The risk or severity of adverse effects can be increased when Palonosetron is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Secobarbital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>The risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of adverse effects can be increased when Triprolidine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The risk or severity of adverse effects can be increased when Metharbital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of adverse effects can be increased when Quinine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The risk or severity of adverse effects can be increased when Methohexital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mephenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mazindol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lisuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Furazolidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paramethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00662</drugbank-id>
      <name>Trimethobenzamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trimethobenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Moricizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Meclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Riluzole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbinoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phensuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Almotriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Naratriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rizatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zaleplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ramelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimenhydrinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Frovatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ergoloid mesylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acetophenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clonazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vigabatrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methyprylon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiamylal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levetiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Decamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alimemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rasagiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Glutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with gamma-Hydroxybutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Camazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01495</drugbank-id>
      <name>Dichloralphenazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dichloralphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Difenoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Delorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorhexadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Drotebanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cloxazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clotiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cinolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01616</drugbank-id>
      <name>Alverine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pargyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02234</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with S-Ethylisothiourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Domoic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Valpromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methapyrilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04821</drugbank-id>
      <name>Nomifensine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nomifensine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Urethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methaqualone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04885</drugbank-id>
      <name>Cilansetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cilansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04903</drugbank-id>
      <name>Pagoclone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pagoclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04917</drugbank-id>
      <name>Renzapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Renzapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ezogabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05227</drugbank-id>
      <name>APD791</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with APD791.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrodotoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brivaracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05542</drugbank-id>
      <name>Naronapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Naronapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05607</drugbank-id>
      <name>PRX-08066</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with PRX-08066.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lumateperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06109</drugbank-id>
      <name>YKP-1358</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with YKP-1358.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lacosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>Tolperisone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tolperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levocetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clomethiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tramiprosate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06529</drugbank-id>
      <name>Ocinaplon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ocinaplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gaboxadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Agomelatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06660</drugbank-id>
      <name>Saredutant</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Saredutant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mepyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fospropofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06753</drugbank-id>
      <name>Triclofos</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triclofos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06797</drugbank-id>
      <name>Mebutamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mebutamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sulthiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08839</drugbank-id>
      <name>Serotonin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Serotonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin enacarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08892</drugbank-id>
      <name>Arbaclofen Placarbil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Arbaclofen Placarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Beclamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09014</drugbank-id>
      <name>Captodiame</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Captodiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brotizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09021</drugbank-id>
      <name>Benzoctamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzoctamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tasimelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eslicarbazepine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09184</drugbank-id>
      <name>Edivoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Edivoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09186</drugbank-id>
      <name>Nisoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nisoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09187</drugbank-id>
      <name>Lortalamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lortalamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09190</drugbank-id>
      <name>Talopram</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Talopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etoperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hydracarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benmoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iproclozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mebanazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Octamoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pheniprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenoxypropazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pivhydrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Safrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Caroxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ramosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pyrantel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alfaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiletamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tricaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11582</drugbank-id>
      <name>Thiocolchicoside</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiocolchicoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11675</drugbank-id>
      <name>Mosapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mosapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11686</drugbank-id>
      <name>Iferanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iferanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tropisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brexanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11889</drugbank-id>
      <name>Lanicemine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lanicemine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11957</drugbank-id>
      <name>Idalopirdine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Idalopirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12071</drugbank-id>
      <name>Vabicaserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vabicaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12105</drugbank-id>
      <name>Imagabalin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Imagabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12110</drugbank-id>
      <name>m-Chlorophenylpiperazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with m-Chlorophenylpiperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12111</drugbank-id>
      <name>MK-212</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with MK-212.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sarpogrelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eplivanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12229</drugbank-id>
      <name>Cerlapirdine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cerlapirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eltanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carisbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12395</drugbank-id>
      <name>Esreboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Esreboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12427</drugbank-id>
      <name>Orvepitant</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Orvepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzodiazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12576</drugbank-id>
      <name>AZD-3043</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with AZD-3043.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Indiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12725</drugbank-id>
      <name>TD-8954</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with TD-8954.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12883</drugbank-id>
      <name>Eltoprazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eltoprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12951</drugbank-id>
      <name>Pivagabine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pivagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Neosaxitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13099</drugbank-id>
      <name>Valnoctamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Valnoctamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13196</drugbank-id>
      <name>Valerian</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Valerian.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13219</drugbank-id>
      <name>Medifoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Medifoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13221</drugbank-id>
      <name>Apronalide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Apronalide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propanidid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Proxibarbal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13303</drugbank-id>
      <name>Febarbamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Febarbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13324</drugbank-id>
      <name>Tetrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13331</drugbank-id>
      <name>Pyrithyldione</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pyrithyldione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13354</drugbank-id>
      <name>Phenprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenprobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13357</drugbank-id>
      <name>Styramate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Styramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pheneturide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromisoval.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13377</drugbank-id>
      <name>Vinbarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vinbarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Neocitrullamon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13402</drugbank-id>
      <name>Acetylglycinamide chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acetylglycinamide chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13414</drugbank-id>
      <name>Fenyramidol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fenyramidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13457</drugbank-id>
      <name>Oxaflozane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxaflozane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13534</drugbank-id>
      <name>Gedocarnil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gedocarnil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13541</drugbank-id>
      <name>Iprazochrome</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iprazochrome.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13572</drugbank-id>
      <name>Emylcamate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Emylcamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13577</drugbank-id>
      <name>Allobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Allobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13588</drugbank-id>
      <name>Naftidrofuryl</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Naftidrofuryl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13623</drugbank-id>
      <name>Fabomotizole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fabomotizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13642</drugbank-id>
      <name>Pridinol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pridinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13662</drugbank-id>
      <name>Hexapropymate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexapropymate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13687</drugbank-id>
      <name>Niaprazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Niaprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vinyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13733</drugbank-id>
      <name>Methylpentynol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylpentynol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13737</drugbank-id>
      <name>Cyclobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13745</drugbank-id>
      <name>Fazadinium bromide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fazadinium bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13754</drugbank-id>
      <name>Mephenoxalone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mephenoxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13770</drugbank-id>
      <name>Vinylbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vinylbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13805</drugbank-id>
      <name>Reposal</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Reposal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13817</drugbank-id>
      <name>Carbromal</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbromal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxefazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lormetazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Harmaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brofaromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13948</drugbank-id>
      <name>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclopropane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13993</drugbank-id>
      <name>MRK-409</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with MRK-409.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cannabidivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Eslicarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxazepam acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14718</drugbank-id>
      <name>Pyrazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pyrazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bentazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Solriamfetol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with RSV-604.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with JNJ-26489112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of adverse effects can be increased when Eletriptan is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The risk or severity of adverse effects can be increased when Methysergide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The risk or severity of adverse effects can be increased when Phenytoin is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Hyaluronidase (ovine).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>The risk or severity of sedation can be increased when Lorpiprazole is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>Tryptophan</name>
      <description>The risk or severity of adverse effects can be increased when Tryptophan is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of adverse effects can be increased when Reserpine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The risk or severity of adverse effects can be increased when Temazepam is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Reboxetine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Venlafaxine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The risk or severity of adverse effects can be increased when Clobazam is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of adverse effects can be increased when Sulpiride is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Alprazolam is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Loxapine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of adverse effects can be increased when Promazine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of adverse effects can be increased when Imipramine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Adinazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clorazepic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Minaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Progabide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Moclobemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlormezanone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Estazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Isocarboxazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01445</drugbank-id>
      <name>Bufotenine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bufotenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fencamfamin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01488</drugbank-id>
      <name>Dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01560</drugbank-id>
      <name>Cathinone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cathinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01954</drugbank-id>
      <name>Rolipram</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rolipram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02959</drugbank-id>
      <name>Oxitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03575</drugbank-id>
      <name>Phencyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phencyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clorgiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04325</drugbank-id>
      <name>Phenethylamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04599</drugbank-id>
      <name>Aniracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aniracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iproniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nialamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lysergic acid diethylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Adipiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06582</drugbank-id>
      <name>Dextofisopam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dextofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etifoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pirlindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Toloxatone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11664</drugbank-id>
      <name>Psilocybin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Psilocybin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12327</drugbank-id>
      <name>Salvinorin A</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Salvinorin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tandospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13082</drugbank-id>
      <name>Nefiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nefiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13352</drugbank-id>
      <name>Deanol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Deanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mebicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13550</drugbank-id>
      <name>Bifemelane</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bifemelane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13601</drugbank-id>
      <name>Oxiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nordazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05077</drugbank-id>
      <name>SLV319</name>
      <description>The risk or severity of adverse effects can be increased when SLV319 is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05372</drugbank-id>
      <name>CP-945598</name>
      <description>The risk or severity of adverse effects can be increased when CP-945598 is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06155</drugbank-id>
      <name>Rimonabant</name>
      <description>The risk or severity of adverse effects can be increased when Rimonabant is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06624</drugbank-id>
      <name>Taranabant</name>
      <description>The risk or severity of adverse effects can be increased when Taranabant is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabidiol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11903</drugbank-id>
      <name>GW842166</name>
      <description>The risk or severity of adverse effects can be increased when GW842166 is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12193</drugbank-id>
      <name>Ajulemic acid</name>
      <description>The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12649</drugbank-id>
      <name>Ibipinabant</name>
      <description>The risk or severity of adverse effects can be increased when Ibipinabant is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13070</drugbank-id>
      <name>Surinabant</name>
      <description>The risk or severity of adverse effects can be increased when Surinabant is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The risk or severity of adverse effects can be increased when Nabiximols is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>The risk or severity of adverse effects can be increased when Palmidrol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14737</drugbank-id>
      <name>Cannabinol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabinol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Morphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of adverse effects can be increased when Codeine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The risk or severity of adverse effects can be increased when Meperidine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of adverse effects can be increased when Oxycodone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of adverse effects can be increased when Naltrexone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of adverse effects can be increased when Fentanyl is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Levorphanol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Remifentanil is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of adverse effects can be increased when Dezocine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The risk or severity of adverse effects can be increased when Diamorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The risk or severity of adverse effects can be increased when Bezitramide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of adverse effects can be increased when Etorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Desomorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Carfentanil is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of adverse effects can be increased when DPDPE is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of adverse effects can be increased when Lofentanil is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The risk or severity of adverse effects can be increased when Eluxadoline is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of adverse effects can be increased when Opium is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of adverse effects can be increased when Normethadone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of adverse effects can be increased when Piritramide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The risk or severity of adverse effects can be increased when Alphaprodine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Nicomorphine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The risk or severity of adverse effects can be increased when Meptazinol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The risk or severity of adverse effects can be increased when Phenoperidine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The risk or severity of adverse effects can be increased when Phenazocine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The risk or severity of adverse effects can be increased when Tilidine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The risk or severity of adverse effects can be increased when Carfentanil, C-11 is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The risk or severity of adverse effects can be increased when Benzhydrocodone is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Esketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The risk or severity of CNS depression can be increased when Naphazoline is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Eszopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of sedation can be increased when Clonidine is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of sedation can be increased when Metoclopramide is combined with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The risk or severity of hypertension can be decreased when Chlordiazepoxide is combined with Phenylephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00913</drugbank-id>
      <name>Anileridine</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09085</drugbank-id>
      <name>Tetracaine</name>
      <description>The therapeutic efficacy of Tetracaine can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The therapeutic efficacy of Chloroform can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13229</drugbank-id>
      <name>Enibomal</name>
      <description>The therapeutic efficacy of Enibomal can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>The therapeutic efficacy of Xenon can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.01</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.99e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-ium-4-olate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>chlordiazepoxide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>299.755</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>299.082539792</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C16H14ClN3O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ANTSCNMPPGJYLG-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>50.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>87.34</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>31.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-2.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>7.06</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>2000 mg/L</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>236-236.5</value>
      <source>Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.44</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>4.8</value>
      <source>MERCK INDEX (1996)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10260</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>3611</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2712</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505044</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00267</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10248513</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50007664</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448932</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000084</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Chlordiazepoxide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL451</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/chlordia.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/lib1225.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/chlordiazepoxide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004797</id>
      <name>GABA-A receptor (anion channel)</name>
      <organism>Humans</organism>
      <actions>
        <action>positive allosteric modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A700</ref-id>
            <pubmed-id>6135616</pubmed-id>
            <citation>Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14867" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-1</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).</specific-function>
        <gene-name>GABRA1</gene-name>
        <locus>5q34-q35</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>252-273
279-300
313-334
422-443</transmembrane-regions>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>9.61</theoretical-pi>
        <molecular-weight>51801.395</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4075</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X13584</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14867</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010561|Gamma-aminobutyric acid receptor subunit alpha-1
MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG
LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC
PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM
TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP
LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID
RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010562|Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)
ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA
CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT
GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA
TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT
TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA
AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA
ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC
ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG
ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC
CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA
GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT
CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG
ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA
TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA
GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC
AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC
TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA
GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT
CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC
AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC
AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC
CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT
ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P47869" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-2</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRA2</gene-name>
        <locus>4p12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>252-273
279-300
313-334
420-441</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>9.41</theoretical-pi>
        <molecular-weight>51325.85</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4076</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S62907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>386422</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P47869</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037005|Gamma-aminobutyric acid receptor subunit alpha-2
MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPG
LGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSC
PLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVM
TAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASV
MIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRM
SRIVFPVLFGTFNLVYWATYLNREPVLGVSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010268|Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2)
ATGAAGACAAAATTGAACATCTACAACATGCAGTTCCTGCTTTTTGTTTTCTTGGTGTGG
GACCCTGCCAGGTTGGTGCTGGCTAACATCCAAGAAGATGAGGCTAAAAATAACATTACC
ATCTTTACGAGAATTCTTGACAGACTTCTGGATGGTTACGATAATCGGCTTAGACCAGGA
CTGGGAGACAGTATTACTGAAGTCTTCACTAACATCTACGTGACCAGTTTTGGCCCTGTC
TCAGATACAGATATGGAATATACAATTGATGTTTTCTTTCGACAAAAATGGAAAGATGAA
CGTTTAAAATTTAAAGGTCCTATGAATATCCTTCGACTAAACAATTTAATGGCTAGCAAA
ATCTGGACTCCAGATACCTTTTTTCACAATGGGAAAAAATCAGTAGCTCATAATATGACA
ATGCCAAATAAGTTGCTTCGAATTCAGGATGATGGGACTCTGCTGTATACCATGAGGCTT
ACAGTTCAAGCTGAATGCCCAATGCACTTGGAGGATTTCCCAATGGATGCTCATTCATGT
CCTCTGAAATTTGGCAGCTATGCATATACAACTTCAGAGGTCACTTATATTTGGACTTAC
AATGCATCTGATTCAGTACAGGTTGCTCCTGATGGCTCTAGGTTAAATCAATATGACCTG
CTGGGCCAATCAATCGGAAAGGAGACAATTAAATCCAGTACAGGTGAATATACTGTAATG
ACAGCTCATTTCCACCTGAAAAGAAAAATTGGGTATTTTGTGATTCAAACCTATCTGCCT
TGCATCATGACTGTCATTCTCTCCCAAGTTTCATTCTGGCTTAACAGAGAATCTGTGCCT
GCAAGAACTGTGTTTGGAGTAACAACTGTCCTAACAATGACAACTCTAAGCATCAGTGCT
CGGAATTCTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTTATTGCTGTTTGT
TATGCATTTGTGTTCTCTGCCCTAATTGAATTTGCAACTGTTAATTACTTCACCAAAAGA
GGATGGGCTTGGGATGGGAAGAGTGTAGTAAATGACAAGAAAAAAGAAAAGGCTTCCGTT
ATGATACAGAACAACGCTTATGCAGTGGCTGTTGCCAATTATGCCCCGAATCTTTCAAAA
GATCCAGTTCTCTCCACCATCTCCAAGAGTGCAACCACGCCAGAACCCAACAAGAAGCCA
GAAAACAAGCCAGCTGAAGCAAAGAAAACTTTCAACAGTGTTAGCAAAATTGACAGAATG
TCCAGAATAGTTTTTCCAGTTTTGTTTGGTACCTTTAATTTAGTTTACTGGGCTACATAT
TTAAACAGAGAACCTGTATTAGGGGTCAGTCCTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of synaptic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>benzodiazepine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurotransmitter levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P34903" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-3</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRA3</gene-name>
        <locus>Xq28</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>277-298
304-325
338-359
458-479</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>8.93</theoretical-pi>
        <molecular-weight>55164.055</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4077</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S62908</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>386424</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>406</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>406</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P34903</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016119|Gamma-aminobutyric acid receptor subunit alpha-3
MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDS
TDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQ
TWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLL
YTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRL
NQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLN
RESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVN
YFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGA
APSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVN
RESAIKGMIRKQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016120|Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3)
ATGATAATCACACAAACAAGTCACTGTTACATGACCAGCCTTGGGATTCTTTTCCTGATT
AATATTCTCCCTGGAACCACTGGTCAAGGGGAATCAAGACGACAAGAACCCGGGGACTTT
GTGAAGCAGGACATTGGCGGGCTGTCTCCTAAGCATGCCCCAGATATTCCTGATGACAGC
ACTGACAACATCACTATCTTCACCAGAATCTTGGATCGTCTTCTGGACGGCTATGACAAC
CGGCTGCGACCTGGGCTTGGAGATGCAGTGACTGAAGTGAAGACTGACATCTACGTGACC
AGTTTTGGCCCTGTGTCAGACACTGACATGGAGTACACTATTGATGTATTTTTTCGGCAG
ACATGGCATGATGAAAGACTGAAATTTGATGGCCCCATGAAGATCCTTCCACTGAACAAT
CTCCTGGCTAGTAAGATCTGGACACCGGACACCTTCTTCCACAATGGCAAGAAATCAGTG
GCTCATAACATGACCACGCCCAACAAGCTGCTCAGATTGGTGGACAACGGAACCCTCCTC
TATACAATGAGGTTAACAATTCATGCTGAGTGTCCCATGCATTTGGAAGATTTTCCCATG
GATGTGCATGCCTGCCCACTGAAGTTTGGAAGCTATGCCTATACAACAGCTGAAGTGGTT
TATTCTTGGACTCTCGGAAAGAACAAATCCGTGGAAGTGGCACAGGATGGTTCTCGCTTG
AACCAGTATGACCTTTTGGGCCATGTTGTTGGGACAGAGATAATCCGGTCTAGTACAGGA
GAATATGTCGTCATGACAACCCACTTCCATCTCAAGCGAAAAATTGGCTACTTTGTGATC
CAGACCTACTTGCCATGTATCATGACTGTCATTCTGTCACAAGTGTCGTTCTGGCTCAAC
AGAGAGTCTGTTCCTGCCCGTACAGTCTTTGGTGTCACCACTGTGCTTACCATGACCACC
TTGAGTATCAGTGCCAGAAATTCCTTACCTAAAGTGGCATATGCGACGGCCATGGACTGG
TTCATAGCCGTCTGTTATGCCTTTGTATTTTCTGCACTGATTGAATTTGCCACTGTCAAC
TATTTCACCAAGCGGAGTTGGGCTTGGGAAGGCAAGAAGGTGCCAGAGGCCCTGGAGATG
AAGAAGAAAACACCAGCAGCCCCAGCAAAGAAAACCAGCACTACCTTCAACATCGTGGGG
ACCACCTATCCCATCAACCTGGCCAAGGACACTGAATTTTCCACCATCTCCAAGGGCGCT
GCTCCCAGTGCCTCCTCAACCCCAACAATCATTGCTTCACCCAAGGCCACCTACGTGCAG
GACAGCCCGACTGAGACCAAGACCTACAACAGTGTCAGCAAGGTTGACAAAATTTCCCGC
ATCATCTTTCCTGTGCTCTTTGCCATATTCAATCTGGTCTATTGGGCCACATATGTCAAC
CGGGAGTCAGCTATCAAGGGCATGATCCGCAAACAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>benzodiazepine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P48169" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-4</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRA4</gene-name>
        <locus>4p12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>259-280
285-306
318-340
524-543</transmembrane-regions>
        <signal-regions>1-35</signal-regions>
        <theoretical-pi>10.0</theoretical-pi>
        <molecular-weight>61622.645</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4078</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U30461</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>905393</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>407</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P48169</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018959|Gamma-aminobutyric acid receptor subunit alpha-4
MVSAKKVPAIALSAGVSFALLRFLCLAVCLNESPGQNQKEEKLCTENFTRILDSLLDGYD
NRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLN
NMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFP
MDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSIT
GEYIVMTVYFHLRRKMGYFMIQTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMT
TLSISARHSLPKVSYATAMDWFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQ
EVPAAPVQREKHPEAPLQNTNANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQES
SKGTPRSYLASSPNPFSRANAAETISAARALPSASPTSIRTGYMPRKASVGSASTRHVFG
SRLQRIKTTVNTIGATGKLSATPPPSAPPPSGSGTSKIDKYARILFPVTFGAFNMVYWVV
YLSKDTMEKSESLM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018960|Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4)
ATGGTTTCTGCCAAGAAGGTACCCGCGATCGCTCTGTCCGCCGGGGTCAGTTTCGCCCTC
CTGCGCTTCCTGTGCCTGGCGGTTTGTTTAAACGAATCCCCAGGACAGAACCAAAAGGAG
GAGAAATTGTGCACAGAAAATTTCACCCGCATCCTGGACAGTTTGCTCGATGGTTATGAC
AACAGGCTGCGTCCTGGATTTGGGGGTCCTGTTACAGAAGTGAAAACTGACATATATGTC
ACCAGCTTTGGACCTGTTTCTGATGTTGAAATGGAATACACAATGGATGTGTTCTTCAGG
CAGACATGGATTGACAAAAGATTAAAATATGACGGCCCCATTGAAATTTTGAGATTGAAC
AATATGATGGTAACGAAAGTGTGGACCCCTGATACTTTCTTCAGGAATGGAAAGAAATCT
GTCTCACATAATATGACAGCTCCAAATAAGCTTTTTAGAATTATGAGAAATGGTACTATT
TTATACACAATGAGACTCACCATAAGTGCGGAGTGTCCCATGAGATTGGTGGATTTTCCC
ATGGATGGTCATGCATGCCCTTTGAAATTCGGGAGTTATGCCTATCCAAAGAGTGAGATG
ATCTATACCTGGACAAAAGGTCCTGAGAAATCAGTTGAAGTTCCGAAGGAGTCTTCCAGC
TTAGTTCAATATGATTTGATTGGGCAAACCGTATCAAGTGAAACCATCAAATCAATTACG
GGTGAATATATTGTTATGACGGTTTACTTCCACCTCAGACGGAAGATGGGTTATTTTATG
ATTCAGACCTATATTCCGTGCATTATGACAGTGATTCTTTCTCAAGTTTCATTTTGGATA
AATAAAGAATCAGTTCCCGCTAGGACTGTATTTGGAATAACAACTGTCCTCACCATGACC
ACACTAAGCATCAGTGCACGACATTCTTTGCCCAAAGTGTCCTATGCTACCGCCATGGAC
TGGTTCATAGCTGTCTGCTTTGCTTTTGTATTTTCGGCCCTTATCGAGTTTGCTGCTGTC
AACTATTTCACCAATATTCAAATGGAAAAAGCCAAAAGGAAGACATCAAAGCCCCCTCAG
GAAGTTCCCGCTGCTCCAGTGCAGAGAGAGAAGCATCCTGAAGCCCCTCTGCAGAATACA
AATGCCAATTTGAACATGAGAAAAAGAACAAATGCTTTGGTTCACTCTGAATCTGATGTT
GGCAACAGAACTGAGGTGGGAAACCATTCAAGCAAATCTTCCACAGTTGTTCAAGAATCT
TCTAAAGGCACACCTCGGTCTTACTTAGCTTCCAGTCCAAACCCATTCAGCCGTGCAAAT
GCAGCTGAAACCATATCTGCAGCAAGAGCACTTCCATCTGCTTCTCCTACTTCTATCCGA
ACTGGATATATGCCTCGAAAGGCTTCAGTTGGATCTGCTTCTACTCGTCACGTGTTTGGA
TCAAGACTGCAGAGGATAAAGACCACAGTTAATACCATAGGGGCTACTGGGAAGTTGTCA
GCTACTCCTCCTCCATCGGCTCCACCACCTTCTGGATCTGGCACAAGTAAAATAGACAAA
TATGCCCGTATTCTCTTTCCAGTCACATTTGGGGCATTTAACATGGTTTATTGGGTTGTT
TATTTATCTAAGGACACTATGGAGAAATCAGAAAGTCTAATGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>benzodiazepine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>central nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P31644" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-5</name>
        <general-function>Transporter activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRA5</gene-name>
        <locus>15q11.2-q12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>260-281
286-307
319-341
428-449</transmembrane-regions>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>9.56</theoretical-pi>
        <molecular-weight>52145.645</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4079</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L08485</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182916</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31644</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010331|Gamma-aminobutyric acid receptor subunit alpha-5
MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGY
DNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPL
NNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDF
PMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTS
TGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTM
TTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAA
KIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYN
SISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010332|Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5)
ATGGACAATGGAATGTTCTCTGGTTTTATCATGATCAAAAACCTCCTTCTCTTTTGTATT
TCCATGAACTTATCCAGTCACTTTGGCTTTTCACAGATGCCAACCAGTTCAGTGAAAGAT
GAGACCAATGACAACATCACGATATTTACCAGGATCTTGGATGGGCTCTTGGATGGCTAC
GACAACAGACTTCGGCCCGGGCTGGGAGAGCGCATCACTCAGGTGAGGACCGACATCTAC
GTCACCAGCTTCGGCCCGGTGTCCGACACGGAAATGGAGTACACCATAGACGTGTTTTTC
CGACAAAGCTGGAAAGATGAAAGGCTTCGGTTTAAGGGGCCCATGCAGCGCCTCCCTCTC
AACAACCTCCTTGCCAGCAAGATCTGGACCCCAGACACGTTCTTCCACAACGGGAAGAAG
TCCATCGCTCACAACATGACCACGCCCAACAAGCTGCTGCGGCTGGAGGACGACGGCACC
CTGCTCTACACCATGCGCTTGACCATCTCTGCAGAGTGCCCCATGCAGCTTGAGGACTTC
CCGATGGATGCGCACGCTTGCCCTCTGAAATTTGGCAGCTATGCGTACCCTAATTCTGAA
GTCGTTTACGTCTGGACCAACGGCTCCACCAAGTCGGTGGTGGTGGCGGAAGATGGCTCC
AGACTGAACCAGTACCACCTGATGGGGCAGACGGTGGGCACTGAGAACATCAGCACCAGC
ACAGGCGAATACACAATCATGACAGCTCACTTCCACCTGAAAAGGAAGATTGGCTACTTT
GTCATCCAGACCTACCTTCCCTGCATAATGACCGTGATCTTATCACAGGTGTCCTTTTGG
CTGAACCGGGAATCAGTCCCAGCCAGGACAGTTTTTGGGGTCACCACGGTGCTGACCATG
ACGACCCTCAGCATCAGCGCCAGGAACTCTCTGCCCAAAGTGGCCTACGCCACCGCCATG
GACTGGTTCATAGCCGTGTGCTATGCCTTCGTCTTCTCGGCGCTGATAGAGTTTGCCACG
GTCAATTACTTTACCAAGAGAGGCTGGGCCTGGGATGGCAAAAAAGCCTTGGAAGCAGCC
AAGATCAAGAAAAAGCGTGAAGTCATACTAAATAAGTCAACAAACGCTTTTACAACTGGG
AAGATGTCTCACCCCCCAAACATTCCGAAGGAACAGACCCCAGCAGGGACGTCGAATACA
ACCTCAGTCTCAGTAAAACCCTCTGAAGAGAAGACTTCTGAAAGCAAAAAGACTTACAAC
AGTATCAGCAAAATTGACAAAATGTCCCGAATCGTATTCCCAGTCTTGTTCGGCACTTTC
AACTTAGTTTACTGGGCAACGTATTTGAATAGGGAGCCGGTGATAAAAGGAGCCGCCTCT
CCAAAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cochlea development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear receptor cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innervation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of defense response to virus by host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenophagy</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q16445" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit alpha-6</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRA6</gene-name>
        <locus>5q34</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>243-264
269-290
301-324
420-441</transmembrane-regions>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>8.4</theoretical-pi>
        <molecular-weight>51023.69</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4080</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRA6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S81944</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1470364</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>409</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>409</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16445</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRA6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit alpha-6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010540|Gamma-aminobutyric acid receptor subunit alpha-6
MASSLPWLCIILWLENALGKLEVEGNFYSENVSRILDNLLEGYDNRLRPGFGGAVTEVKT
DIYVTSFGPVSDVEMEYTMDVFFRQTWTDERLKFGGPTEILSLNNLMVSKIWTPDTFFRN
GKKSIAHNMTTPNKLFRIMQNGTILYTMRLTINADCPMRLVNFPMDGHACPLKFGSYAYP
KSEIIYTWKKGPLYSVEVPEESSSLLQYDLIGQTVSSETIKSNTGEYVIMTVYFHLQRKM
GYFMIQIYTPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLPKVSYA
TAMDWFIAVCFAFVFSALIEFAAVNYFTNLQTQKAKRKAQFAAPPTVTISKATEPLEAEI
VLHPDSKYHLKKRITSLSLPIVSSSEANKVLTRAPILQSTPVTPPPLSPAFGGTSKIDQY
SRILFPVAFAGFNLVYWVVYLSKDTMEVSSSVE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010541|Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6)
ATGGCGTCGTCTCTGCCCTGGCTGTGCATTATTCTGTGGCTAGAAAATGCCCTAGGGAAA
CTCGAAGTTGAAGGCAACTTCTACTCAGAAAACGTCAGTCGGATCCTGGACAACTTGCTT
GAAGGCTATGACAATCGGCTGCGGCCGGGATTTGGAGGTGCTGTCACTGAAGTCAAAACA
GACATTTATGTGACCAGTTTTGGGCCCGTGTCAGATGTGGAGATGGAGTATACGATGGAT
GTTTTTTTCCGCCAGACCTGGACTGATGAGAGGTTGAAGTTTGGGGGGCCAACTGAGATT
CTGAGTCTGAATAATTTGATGGTCAGTAAAATCTGGACGCCTGACACCTTTTTCAGAAAT
GGTAAAAAGTCCATTGCTCACAACATGACAACTCCTAATAAACTCTTCAGAATAATGCAG
AATGGAACCATTTTATACACCATGAGGCTTACCATCAATGCTGACTGTCCCATGAGGCTG
GTTAACTTTCCTATGGATGGGCATGCTTGTCCACTCAAGTTTGGGAGCTATGCTTATCCC
AAAAGTGAAATCATATATACGTGGAAAAAAGGACCACTTTACTCAGTAGAAGTCCCAGAA
GAATCTTCAAGCCTTCTCCAGTATGATCTGATTGGACAAACAGTATCTAGTGAGACAATT
AAATCTAACACAGGTGAATACGTTATAATGACAGTTTACTTCCACTTGCAAAGGAAGATG
GGCTACTTCATGATACAGATATACACTCCTTGCATTATGACAGTCATTCTTTCCCAGGTG
TCTTTCTGGATTAATAAGGAGTCCGTCCCAGCAAGAACTGTTTTTGGGATCACCACTGTT
TTAACTATGACCACTTTGAGCATCAGTGCCCGGCACTCTTTGCCAAAAGTGTCATATGCC
ACTGCCATGGATTGGTTCATAGCTGTTTGCTTTGCATTCGTCTTCTCTGCGCTTATCGAG
TTCGCAGCTGTCAACTACTTTACCAATCTTCAGACACAGAAGGCCAAAAGGAAGGCACAG
TTTGCAGCCCCACCCACAGTGACAATATCAAAAGCTACTGAACCTTTGGAAGCTGAGATT
GTTTTGCATCCTGACTCCAAATATCATCTGAAGAAAAGGATCACTTCTCTGTCTTTGCCA
ATAGTTTCATCTTCCGAGGCCAATAAAGTGCTCACGAGAGCGCCCATCTTACAATCAACA
CCTGTCACACCCCCACCACTCTCGCCAGCCTTTGGAGGCACCAGTAAAATAGACCAGTAT
TCTCGAATTCTCTTCCCAGTTGCATTTGCAGGATTCAACCTTGTGTACTGGGTAGTTTAT
CTTTCCAAAGATACAATGGAAGTCAGTAGCAGTGTTGAATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>benzodiazepine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P18505" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit beta-1</name>
        <general-function>Ligand-gated ion channel activity</general-function>
        <specific-function>Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).</specific-function>
        <gene-name>GABRB1</gene-name>
        <locus>4p12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>246-267
271-293
305-327
452-473</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>9.01</theoretical-pi>
        <molecular-weight>54234.085</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4081</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X14767</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>410</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18505</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit beta-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004603|Gamma-aminobutyric acid receptor subunit beta-1
MWTVQNRESLGLLSFPVMITMVCCAHSTNEPSNMSYVKETVDRLLKGYDIRLRPDFGGPP
VDVGMRIDVASIDMVSEVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVADQLWVPD
TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE
SYGYTTDDIEFYWNGGEGAVTGVNKIELPQFSIVDYKMVSKKVEFTTGAYPRLSLSFRLK
RNIGYFILQTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLPKI
PYVKAIDIYLMGCFVFVFLALLEYAFVNYIFFGKGPQKKGASKQDQSANEKNKLEMNKVQ
VDAHGNILLSTLEIRNETSGSEVLTSVSDPKATMYSYDSASIQYRKPLSSREAYGRALDR
HGVPSKGRIRRRASQLKVKIPDLTDVNSIDKWSRMFFPITFSLFNVVYWLYYVH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020610|Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1)
ATGTGGACAGTACAAAATCGAGAGAGTCTGGGGCTTCTCTCTTTCCCTGTGATGATTACC
ATGGTCTGTTGTGCACACAGCACCAATGAACCCAGCAACATGTCATACGTGAAAGAGACA
GTGGACAGATTGCTCAAAGGATATGACATTCGCTTGCGGCCGGACTTCGGAGGGCCCCCC
GTCGACGTTGGGATGCGGATCGATGTCGCCAGCATAGACATGGTCTCCGAAGTGAATATG
GATTATACACTCACCATGTATTTCCAGCAGTCTTGGAAAGACAAAAGGCTTTCTTATTCT
GGAATCCCACTGAACCTCACCCTAGACAATAGGGTAGCTGACCAACTCTGGGTACCAGAC
ACCTACTTTCTGAATGACAAGAAATCATTTGTGCATGGGGTCACAGTGAAAAATCGAATG
ATTCGACTGCATCCTGATGGAACAGTTCTCTATGGACTCCGAATCACAACCACAGCTGCA
TGTATGATGGATCTTCGAAGATATCCACTGGATGAGCAGAACTGCACCCTGGAGATCGAA
AGTTATGGCTATACCACTGATGACATTGAATTTTACTGGAATGGAGGAGAAGGGGCAGTC
ACTGGTGTTAATAAAATCGAACTTCCTCAATTTTCAATTGTTGACTACAAGATGGTGTCT
AAGAAGGTGGAGTTCACAACAGGAGCGTATCCACGACTGTCACTAAGTTTTCGTCTAAAG
AGAAACATTGGTTACTTCATTTTGCAAACCTACATGCCTTCTACACTGATTACAATTCTG
TCCTGGGTGTCTTTTTGGATCAACTATGATGCATCTGCAGCCAGAGTCGCACTAGGAATC
ACGACAGTGCTTACAATGACAACCATCAGCACCCACCTCAGGGAGACCCTGCCAAAGATC
CCTTATGTCAAAGCGATTGATATTTATCTGATGGGTTGCTTTGTGTTTGTGTTCCTGGCT
CTGCTGGAGTATGCCTTTGTAAATTACATCTTCTTTGGGAAAGGCCCTCAGAAAAAGGGA
GCTAGCAAACAAGACCAGAGTGCCAATGAGAAGAATAAACTGGAGATGAATAAAGTCCAG
GTCGACGCCCACGGTAACATTCTCCTCAGCACCCTGGAAATCCGGAATGAGACGAGTGGC
TCGGAAGTGCTCACGAGCGTGAGCGACCCCAAGGCCACCATGTACTCCTATGACAGCGCC
AGCATCCAGTACCGCAAGCCCCTGAGCAGCCGCGAGGCCTACGGGCGCGCCCTGGACCGG
CACGGGGTACCCAGCAAGGGGCGCATCCGCAGGCGTGCCTCCCAGCTCAAAGTCAAGATC
CCCGACTTGACTGATGTGAATTCCATAGACAAGTGGTCCCGAATGTTTTTCCCCATCACC
TTTTCTCTTTTTAATGTCGTCTATTGGCTTTACTATGTACACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>central nervous system neuron development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovulation cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P47870" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit beta-2</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.</specific-function>
        <gene-name>GABRB2</gene-name>
        <locus>5q34</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>245-266
270-292
304-326
490-511</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>9.66</theoretical-pi>
        <molecular-weight>59149.895</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4082</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S67368</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>455946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>411</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P47870</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit beta-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037195|Gamma-aminobutyric acid receptor subunit beta-2
MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPV
AVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDT
YFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIES
YGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKR
NIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIP
YVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKI
FYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEA
VMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPD
LTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011685|Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2)
ATGTGGAGAGTGCGGAAAAGGGGCTACTTTGGGATTTGGTCCTTCCCCTTAATAATCGCC
GCTGTCTGTGCGCAGAGTGTCAATGACCCTAGTAATATGTCGCTGGTTAAAGAGACGGTG
GATAGACTCCTGAAAGGCTATGACATTCGTCTGAGACCAGATTTTGGAGGTCCCCCCGTG
GCTGTGGGGATGAACATTGACATTGCCAGCATCGATATGGTTTCTGAAGTCAATATGGAT
TATACCTTGACAATGTACTTTCAACAAGCCTGGAGAGATAAGAGGCTGTCCTATAATGTA
ATACCTTTAAACTTGACTCTGGACAACAGAGTGGCAGACCAGCTCTGGGTGCCTGATACC
TATTTCCTGAACGATAAGAAGTCATTTGTGCACGGAGTGACTGTTAAGAACCGCATGATT
CGCCTGCATCCTGATGGCACCGTCCTTTATGGACTCAGAATCACAACCACAGCTGCCTGC
ATGATGGACCTAAGGAGGTACCCACTGGATGAACAAAACTGCACCTTGGAAATTGAGAGC
TATGGATACACAACTGATGACATTGAGTTTTACTGGCGTGGCGATGATAATGCAGTAACA
GGAGTAACGAAAATTGAACTTCCACAGTTCTCTATTGTAGATTACAAACTTATCACCAAG
AAGGTTGTTTTTTCCACAGGTTCCTATCCCAGGTTATCCCTCAGCTTTAAGCTTAAGAGA
AACATTGGCTACTTTATCCTGCAAACATACATGCCTTCCATCCTGATTACCATCCTCTCC
TGGGTCTCCTTCTGGATTAATTACGATGCTTCAGCTGCAAGGGTGGCATTAGGAATCACA
ACTGTCCTCACAATGACCACAATCAACACCCACCTCCGGGAAACTCTCCCTAAAATCCCC
TATGTGAAGGCCATTGACATGTACCTGATGGGGTGCTTTGTCTTCGTTTTCATGGCCCTT
CTGGAATATGCCCTAGTCAACTACATCTTCTTTGGGAGGGGGCCCCAACGCCAAAAGAAA
GCAGCTGAGAAGGCTGCCAGTGCCAACAATGAGAAGATGCGCCTGGATGTCAACAAGATG
GACCCCCATGAGAACATCTTACTGAGCACTCTCGAGATAAAAAATGAAATGGCCACATCT
GAGGCTGTGATGGGACTTGGAGACCCCAGAAGCACAATGCTAGCCTATGATGCCTCCAGC
ATCCAGTATCGGAAAGCTGGGTTGCCCAGGCATAGTTTTGGCCGAAATGCTCTGGAACGA
CATGTGGCGCAAAAGAAAAGTCGCCTGAGGAGACGCGCCTCCCAACTGAAAATCACCATC
CCTGACTTGACTGATGTGAATGCCATAGATCGGTGGTCCCGCATATTCTTCCCAGTGGTT
TTTTCCTTCTTCAACATCGTCTATTGGCTTTATTATGTGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cochlea development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear receptor cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innervation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P28472" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit beta-3</name>
        <general-function>Gaba-gated chloride ion channel activity</general-function>
        <specific-function>Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.</specific-function>
        <gene-name>GABRB3</gene-name>
        <locus>15q11.2-q12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>246-267
271-293
305-327
451-472</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>9.41</theoretical-pi>
        <molecular-weight>54115.04</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4083</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GABRB3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M82919</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182925</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>412</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>412</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28472</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRB3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit beta-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004605|Gamma-aminobutyric acid receptor subunit beta-3
MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPP
VCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPD
TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE
SYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLK
RNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKI
PYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNR
VDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRS
LPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016761|Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3)
ATGTGGGGCCTTGCGGGAGGAAGGCTTTTCGGCATCTTCTCGGCCCCGGTGCTGGTGGCT
GTGGTGTGCTGCGCCCAGAGTGTGAACGATCCCGGGAACATGTCCTTTGTGAAGGAGACG
GTGGACAAGCTGTTGAAAGGCTACGACATTCGCCTAAGACCCGACTTCGGGGGTCCCCCG
GTCTGCGTGGGGATGAACATCGACATCGCCAGCATCGACATGGTTTCCGAAGTCAACATG
GATTATACCTTAACCATGTATTTTCAACAATATTGGAGAGATAAAAGGCTCGCCTATTCT
GGGATCCCTCTCAACCTCACGCTTGACAATCGAGTGGCTGACCAGCTATGGGTGCCCGAC
ACATATTTCTTAAATGACAAAAAGTCATTTGTGCATGGAGTGACAGTGAAAAACCGCATG
ATCCGTCTTCACCCTGATGGGACAGTGCTGTATGGGCTCAGAATCACCACGACAGCAGCA
TGCATGATGGACCTCAGGAGATACCCCCTGGACGAGCAGAACTGCACTCTGGAAATTGAA
AGCTATGGCTACACCACGGATGACATTGAGTTTTACTGGCGAGGCGGGGACAAGGCTGTT
ACCGGAGTGGAAAGGATTGAGCTCCCGCAGTTCTCCATCGTGGAGCACCGTCTGGTCTCG
AGGAATGTTGTCTTCGCCACAGGTGCCTATCCTCGACTGTCACTGAGCTTTCGGTTGAAG
AGGAACATTGGATACTTCATTCTTCAGACTTATATGCCCTCTATACTGATAACGATTCTG
TCGTGGGTGTCCTTCTGGATCAATTATGATGCATCTGCTGCTAGAGTTGCCCTCGGGATC
ACAACTGTGCTGACAATGACAACCATCAACACCCACCTTCGGGAGACCTTGCCCAAAATC
CCCTATGTCAAAGCCATTGACATGTACCTTATGGGCTGCTTCGTCTTTGTGTTCCTGGCC
CTTCTGGAGTATGCCTTTGTCAACTACATTTTCTTTGGAAGAGGCCCTCAAAGGCAGAAG
AAGCTTGCAGAAAAGACAGCCAAGGCAAAGAATGACCGTTCAAAGAGCGAAAGCAACCGG
GTGGATGCTCATGGAAATATTCTGTTGACATCGCTGGAAGTTCACAATGAAATGAATGAG
GTCTCAGGCGGCATTGGCGATACCAGGAATTCAGCAATATCCTTTGACAACTCAGGAATC
CAGTACAGGAAACAGAGCATGCCTCGAGAAGGGCATGGGCGATTCCTGGGGGACAGAAGC
CTCCCGCACAAGAAGACCCATCTACGGAGGAGGTCTTCACAGCTCAAAATTAAAATACCT
GATCTAACCGATGTGAATGCCATAGACAGATGGTCCAGGATCGTGTTTCCATTCACTTTT
TCTCTTTTCAACTTAGTTTACTGGCTGTACTATGTTAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-gated chloride ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cochlea development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibitory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inner ear receptor cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innervation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>palate development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O14764" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit delta</name>
        <general-function>Gaba-a receptor activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRD</gene-name>
        <locus>1p|1p36.3</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>249-271
275-297
309-331
430-452</transmembrane-regions>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>8.73</theoretical-pi>
        <molecular-weight>50707.835</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4084</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF016917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2388693</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O14764</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit delta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012501|Gamma-aminobutyric acid receptor subunit delta
MDAPARLLAPLLLLCAQQLRGTRAMNDIGDYVGSNLEISWLPNLDGLIAGYARNFRPGIG
GPPVNVALALEVASIDHISEANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVDKLW
LPDTFIVNAKSAWFHDVTVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECML
DLESYGYSSEDIVYYWSESQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLH
FHLRRNRGVYIIQSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSS
LPRASAIKALDVYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSRPRAEMDVRNAI
VLFSLSAAGVTQELAISRRQRRVPGNLMGSYRSVGVETGETKKEGAARSGGQGGIRARLR
PIDADTIDIYARAVFPAAFAAVNVIYWAAYAM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012502|Gamma-aminobutyric acid receptor subunit delta (GABRD)
ATGGACGCGCCCGCCCGGCTGCTGGCCCCGCTCCTGCTCCTCTGCGCGCAGCAGCTCCGC
GGCACCAGAGCGATGAATGACATCGGCGACTACGTGGGCTCCAACCTGGAGATCTCCTGG
CTCCCCAACCTGGACGGGCTGATAGCCGGCTACGCCCGCAACTTCCGGCCTGGCATCGGA
GGCCCCCCCGTGAATGTGGCCCTTGCCCTGGAGGTGGCCAGCATCGACCACATCTCAGAG
GCCAACATGGAGTACACCATGACGGTGTTCCTGCACCAGAGCTGGCGGGACAGCAGGCTC
TCCTACAACCACACCAACGAGACCCTGGGTCTGGACAGCCGCTTCGTGGACAAGCTGTGG
CTGCCCGACACCTTCATCGTGAACGCCAAGTCGGCCTGGTTCCACGACGTGACGGTGGAG
AACAAGCTCATCCGGCTGCAGCCCGACGGCGTGATCCTGTACAGCATCCGAATCACCTCC
ACTGTGGCCTGCGACATGGACCTGGCCAAATACCCCATGGACGAGCAGGAGTGCATGCTG
GACCTGGAGAGCTACGGTTACTCATCGGAGGACATCGTCTACTACTGGTCGGAGAGCCAG
GAGCACATCCACGGGCTGGACAAGCTGCAGCTGGCGCAGTTCACCATCACCAGCTACCGC
TTCACCACGGAGCTGATGAACTTCAAGTCCGCTGGCCAGTTCCCACGGCTCAGCCTGCAC
TTCCACCTGCGGAGGAACCGCGGCGTGTACATCATCCAATCCTACATGCCCTCCGTCCTG
CTGGTCGCCATGTCCTGGGTCTCCTTCTGGATCAGCCAGGCGGCGGTGCCCGCCAGGGTG
TCTCTAGGCATCACCACGGTGCTGACGATGACCACGCTCATGGTCAGTGCCCGCTCCTCC
CTGCCACGGGCATCAGCCATCAAGGCACTGGACGTCTACTTCTGGATCTGCTATGTCTTC
GTGTTTGCCGCCCTGGTGGAGTACGCCTTTGCTCATTTCAACGCCGACTACAGGAAGAAG
CAGAAGGCCAAGGTCAAGGTCTCCAGGCCGAGGGCAGAGATGGACGTGAGGAACGCCATT
GTCCTCTTCTCCCTCTCTGCTGCCGGCGTCACGCAGGAGCTGGCCATCTCCCGCCGGCAG
CGCCGCGTCCCGGGGAACCTGATGGGCTCCTACAGGTCGGTGGGGGTGGAGACAGGGGAG
ACGAAGAAGGAGGGGGCAGCCCGCTCAGGAGGCCAGGGGGGCATCCGTGCCCGGCTCAGG
CCCATCGACGCAGACACCATTGACATTTACGCCCGCGCTGTGTTCCCTGCGGCGTTTGCG
GCCGTCAATGTCATCTACTGGGCGGCATACGCCATGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P78334" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit epsilon</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRE</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>254-274
281-301
344-364
486-506</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>8.09</theoretical-pi>
        <molecular-weight>57971.175</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4085</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U66661</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1857126</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P78334</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit epsilon</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006923|Gamma-aminobutyric acid receptor subunit epsilon
MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETE
TGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDI
IFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKD
GKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSW
KLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFW
IKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAV
LNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEER
PSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRL
DNYSRVVFPVTFFFFNVLYWLVCLNL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020703|Gamma-aminobutyric acid receptor subunit epsilon (GABRE)
ATGTTGTCCAAAGTTCTTCCAGTCCTCCTAGGCATCTTATTGATCCTCCAGTCGAGGGTC
GAGGGACCTCAGACTGAATCAAAGAATGAAGCCTCTTCCCGTGATGTTGTCTATGGCCCC
CAGCCCCAGCCTCTGGAAAATCAGCTCCTCTCTGAGGAAACAAAGTCAACTGAGACTGAG
ACTGGGAGCAGAGTTGGCAAACTGCCAGAAGCCTCTCGCATCCTGAACACTATCCTGAGT
AATTATGACCACAAACTGCGCCCTGGCATTGGAGAGAAGCCCACTGTGGTCACTGTTGAG
ATCTCCGTCAACAGCCTTGGTCCTCTCTCTATCCTAGACATGGAATACACCATTGACATC
ATCTTCTCCCAGACCTGGTACGACGAACGCCTCTGTTACAACGACACCTTTGAGTCTCTT
GTTCTGAATGGCAATGTGGTGAGCCAGCTATGGATCCCGGACACCTTTTTTAGGAATTCT
AAGAGGACCCACGAGCATGAGATCACCATGCCCAACCAGATGGTCCGCATCTACAAGGAT
GGCAAGGTGTTGTACACAATTAGGATGACCATTGATGCCGGATGCTCACTCCACATGCTC
AGATTTCCAATGGATTCTCACTCTTGCCCTCTATCTTTCTCTAGCTTTTCCTATCCTGAG
AATGAGATGATCTACAAGTGGGAAAATTTCAAGCTTGAAATCAATGAGAAGAACTCCTGG
AAGCTCTTCCAGTTTGATTTTACAGGAGTGAGCAACAAAACTGAAATAATCACAACCCCA
GTTGGTGACTTCATGGTCATGACGATTTTCTTCAATGTGAGCAGGCGGTTTGGCTATGTT
GCCTTTCAAAACTATGTCCCTTCTTCCGTGACCACGATGCTCTCCTGGGTTTCCTTTTGG
ATCAAGACAGAGTCTGCTCCAGCCCGGACCTCTCTAGGGATCACCTCTGTTCTGACCATG
ACCACGTTGGGCACCTTTTCTCGTAAGAATTTCCCGCGTGTCTCCTATATCACAGCCTTG
GATTTCTATATCGCCATCTGCTTCGTCTTCTGCTTCTGCGCTCTGTTGGAGTTTGCTGTG
CTCAACTTCCTGATCTACAACCAGACAAAAGCCCATGCTTCTCCTAAACTCCGCCATCCT
CGTATCAATAGCCGTGCCCATGCCCGTACCCGTGCACGTTCCCGAGCCTGTGCCCGCCAA
CATCAGGAAGCTTTTGTGTGCCAGATTGTCACCACTGAGGGAAGTGATGGAGAGGAGCGC
CCGTCTTGCTCAGCCCAGCAGCCCCCTAGCCCAGGTAGCCCTGAGGGTCCCCGCAGCCTC
TGCTCCAAGCTGGCCTGCTGTGAGTGGTGCAAGCGTTTTAAGAAGTACTTCTGCATGGTC
CCCGATTGTGAGGGCAGTACCTGGCAGCAGGGCCGCCTCTGCATCCATGTCTACCGCCTG
GATAACTACTCGAGAGTTGTTTTCCCAGTGACTTTCTTCTTCTTCAATGTGCTCTACTGG
CTTGTTTGCCTTAACTTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q8N1C3" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit gamma-1</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRG1</gene-name>
        <locus>4p12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>273-294
299-320
332-354
445-465</transmembrane-regions>
        <signal-regions>1-35</signal-regions>
        <theoretical-pi>8.23</theoretical-pi>
        <molecular-weight>53594.49</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4086</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AK122845</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>193783776</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8N1C3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRG1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit gamma-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012496|Gamma-aminobutyric acid receptor subunit gamma-1
MGPLKAFLFSPFLLRSQSRGVRLVFLLLTLHLGNCVDKADDEDDEDLTVNKTWVLAPKIH
EGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFAQTWF
DSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDGRVLYTL
RLTINAECYLQLHNFPMDEHSCPLEFSSYGYPKNEIEYKWKKPSVEVADPKYWRLYQFAF
VGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVLSWVSFWINKDAVP
ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFAALMEYGTLHYFTSN
QKGKTATKDRKLKNKASMTPGLHPGSTLIPMNNISVPQEDDYGYQCLEGKDCASFFCCFE
DCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLVYWVGYLYL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012497|Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1)
ATGGGTCCTTTGAAAGCTTTTCTCTTCTCCCCTTTTCTTCTGCGGAGTCAAAGTAGAGGG
GTGAGGTTGGTCTTCTTGTTACTGACCCTGCATTTGGGAAACTGTGTTGATAAGGCAGAT
GATGAAGATGATGAGGATTTAACGGTGAACAAAACCTGGGTCTTGGCCCCAAAAATTCAT
GAAGGAGATATCACACAAATTCTGAATTCATTGCTTCAAGGCTATGACAATAAACTTCGT
CCAGATATAGGAGTGAGGCCCACAGTAATTGAAACTGATGTTTATGTAAACAGCATTGGA
CCAGTTGATCCAATTAATATGGAATATACAATAGATATAATTTTTGCCCAAACCTGGTTT
GACAGTCGTTTAAAATTCAATAGTACCATGAAAGTGCTTATGCTTAACAGTAATATGGTT
GGAAAAATTTGGATTCCTGACACTTTCTTCAGAAACTCAAGAAAATCTGATGCTCACTGG
ATAACAACTCCTAATCGTCTGCTTCGAATTTGGAATGATGGACGAGTTCTGTATACTCTA
AGATTGACAATTAATGCAGAATGTTATCTTCAGCTTCATAACTTTCCCATGGATGAACAT
TCCTGTCCACTGGAATTTTCAAGCTATGGATACCCTAAAAATGAAATTGAGTATAAGTGG
AAAAAGCCCTCCGTAGAAGTGGCTGATCCTAAATACTGGAGATTATATCAGTTTGCATTT
GTAGGGTTACGGAACTCAACTGAAATCACTCACACGATCTCTGGGGATTATGTTATCATG
ACAATTTTTTTTGACCTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCA
TGCATTCTGACAGTTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGCCT
GCAAGAACATCGTTGGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACAATTGCC
AGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTTCTGTTTGT
TTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTTTACCAGCAAC
CAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCCTCGATGACTCCT
GGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTGCCGCAAGAAGAT
GATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCTTCTGTTGCTTTGAA
GACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACGCATTGCCAAAATTGAC
TCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTCAACTTGGTTTATTGGGTT
GGCTATCTTTACTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P18507" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit gamma-2</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.</specific-function>
        <gene-name>GABRG2</gene-name>
        <locus>5q31.1-q33.1</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>274-296
300-322
334-356
444-466</transmembrane-regions>
        <signal-regions>1-39</signal-regions>
        <theoretical-pi>8.6</theoretical-pi>
        <molecular-weight>54161.78</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4087</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X15376</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18507</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit gamma-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006917|Gamma-aminobutyric acid receptor subunit gamma-2
MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK
VPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQT
WYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLY
TLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQF
SFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDA
VPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFV
SNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCC
FEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019445|Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2)
ATGAGTTCGCCAAATATATGGAGCACAGGAAGCTCAGTCTACTCGACTCCTGTATTTTCA
CAGAAAATGACGGTGTGGATTCTGCTCCTGCTGTCGCTCTACCCTGGCTTCACTAGCCAG
AAATCTGATGATGACTATGAAGATTATGCTTCTAACAAAACATGGGTCTTGACTCCAAAA
GTTCCTGAGGGTGATGTCACTGTCATCTTAAACAACCTGCTGGAAGGATATGACAATAAA
CTTCGGCCTGATATAGGAGTGAAGCCAACGTTAATTCACACAGACATGTATGTGAATAGC
ATTGGTCCAGTGAACGCTATCAATATGGAATACACTATTGATATATTTTTTGCGCAAACG
TGGTATGACAGACGTTTGAAATTTAACAGCACCATTAAAGTCCTCCGATTGAACAGCAAC
ATGGTGGGGAAAATCTGGATTCCAGACACTTTCTTCAGAAATTCCAAAAAAGCTGATGCA
CACTGGATCACCACCCCCAACAGGATGCTGAGAATTTGGAATGATGGTCGAGTGCTCTAC
ACCCTAAGGTTGACAATTGATGCTGAGTGCCAATTACAATTGCACAACTTTCCAATGGAT
GAACACTCCTGCCCCTTGGAGTTCTCCAGTTATGGCTATCCACGTGAAGAAATTGTTTAT
CAATGGAAGCGAAGTTCTGTTGAAGTGGGCGACACAAGATCCTGGAGGCTTTATCAATTC
TCATTTGTTGGTCTAAGAAATACCACCGAAGTAGTGAAGACAACTTCCGGAGATTATGTG
GTCATGTCTGTCTACTTTGATCTGAGCAGAAGAATGGGATACTTTACCATCCAGACCTAT
ATCCCCTGCACACTCATTGTCGTCCTATCCTGGGTGTCTTTCTGGATCAATAAGGATGCT
GTTCCAGCCAGAACATCTTTAGGTATCACCACTGTCCTGACAATGACCACCCTCAGCACC
ATTGCCCGGAAATCGCTCCCCAAGGTCTCCTATGTCACAGCGATGGATCTCTTTGTATCT
GTTTGTTTCATCTTTGTCTTCTCTGCTCTGGTGGAGTATGGCACCTTGCATTATTTTGTC
AGCAACCGGAAACCAAGCAAGGACAAAGATAAAAAGAAGAAAAACCCTGCCCCTACCATT
GATATCCGCCCAAGATCAGCAACCATTCAAATGAATAATGCTACACACCTTCAAGAGAGA
GATGAAGAGTACGGCTATGAGTGTCTGGACGGCAAGGACTGTGCCAGTTTTTTCTGCTGT
TTTGAAGATTGTCGAACAGGAGCTTGGAGACATGGGAGGATACATATCCGCATTGCCAAA
ATGGACTCCTATGCTCGGATCTTCTTCCCCACTGCCTTCTGCCTGTTTAATCTGGTCTAT
TGGGTCTCCTACCTCTACCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>benzodiazepine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q99928" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit gamma-3</name>
        <general-function>Inhibitory extracellular ligand-gated ion channel activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRG3</gene-name>
        <locus>15q12</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>255-277
281-303
315-337
444-467</transmembrane-regions>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>7.58</theoretical-pi>
        <molecular-weight>54288.16</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4088</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S82769</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1754749</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q99928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRG3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit gamma-3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006921|Gamma-aminobutyric acid receptor subunit gamma-3
MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDK
KLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNS
NMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPM
DEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDY
VVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLS
TIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDS
SRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCC
YEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012498|Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3)
ATGGCCCCGAAGCTGCTGCTCCTCCTCTGCCTGTTCTCGGGCTTGCACGCGCGGTCCAGA
AAGGTGGAAGAGGATGAATATGAAGATTCATCATCAAACCAAAAGTGGGTCTTGGCTCCA
AAATCCCAAGACACCGACGTGACTCTTATTCTCAACAAGTTGCTAAGAGAATATGATAAA
AAGCTGAGGCCAGATATTGGAATAAAACCGACCGTAATTGACGTTGACATTTATGTTAAC
AGCATTGGTCCTGTGTCATCAATAAACATGGAATACCAAATTGACATATTTTTTGCTCAG
ACCTGGACAGATAGTCGCCTTCGATTCAACAGCACAATGAAAATTCTTACTCTGAACAGC
AACATGGTGGGGTTAATCTGGATCCCAGACACCATCTTCCGCAATTCTAAAACCGCAGAG
GCTCACTGGATCACCACACCCAATCAGCTCCTCCGGATTTGGAATGACGGGAAAATCCTT
TACACTTTGAGGCTCACCATCAATGCTGAGTGCCAGCTGCAGCTGCACAACTTCCCCATG
GACGAACACTCCTGCCCGCTGATTTTCTCCAGCTATGGCTATCCCAAAGAAGAAATGATT
TATAGATGGAGAAAAAATTCAGTGGAGGCAGCTGACCAGAAATCATGGCGGCTTTATCAG
TTTGACTTCATGGGCCTCAGAAACACCACAGAAATCGTGACAACGTCTGCAGGTAGGAAT
TTACTGAAAGAGGCACAGCTCTCAAAAGCCAGAGAGGCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inhibitory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gamma-aminobutyric acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O00591" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit pi</name>
        <general-function>Gaba-a receptor activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone.</specific-function>
        <gene-name>GABRP</gene-name>
        <locus>5q33-q34</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>243-266
270-292
305-327
417-438</transmembrane-regions>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>6.99</theoretical-pi>
        <molecular-weight>50639.735</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4089</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U95367</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2197001</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00591</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRP_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit pi</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017152|Gamma-aminobutyric acid receptor subunit pi
MNYSLHLAFVCLSLFTERMCIQGSQFNVEVGRSDKLSLPGFENLTAGYNKFLRPNFGGEP
VQIALTLDIASISSISESNMDYTATIYLRQRWMDQRLVFEGNKSFTLDARLVEFLWVPDT
YIVESKKSFLHEVTVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLES
WGYDGNDVEFTWLRGNDSVRGLEHLRLAQYTIERYFTLVTRSQQETGNYTRLVLQFELRR
NVLYFILETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTN
CFIKAIDVYLGICFSFVFGALLEYAVAHYSSLQQMAAKDRGTTKEVEEVSITNIINSSIS
SFKRKISFASIEISSDNVDYSDLTMKTSDKFKFVFREKMGRIVDYFTIQNPSNVDHYSKL
LFPLIFMLANVFYWAYYMYF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017153|Gamma-aminobutyric acid receptor subunit pi (GABRP)
ATGAACTACAGCCTCCACTTGGCCTTCGTGTGTCTGAGTCTCTTCACTGAGAGGATGTGC
ATCCAGGGGAGTCAGTTCAACGTCGAGGTCGGCAGAAGTGACAAGCTTTCCCTGCCTGGC
TTTGAGAACCTCACAGCAGGATATAACAAATTTCTCAGGCCCAATTTTGGTGGAGAACCC
GTACAGATAGCGCTGACTCTGGACATTGCAAGTATCTCTAGCATTTCAGAGAGTAACATG
GACTACACAGCCACCATATACCTCCGACAGCGCTGGATGGACCAGCGGCTGGTGTTTGAA
GGCAACAAGAGCTTCACTCTGGATGCCCGCCTCGTGGAGTTCCTCTGGGTGCCAGATACT
TACATTGTGGAGTCCAAGAAGTCCTTCCTCCATGAAGTCACTGTGGGAAACAGGCTCATC
CGCCTCTTCTCCAATGGCACGGTCCTGTATGCCCTCAGAATCACGACAACTGTTGCATGT
AACATGGATCTGTCTAAATACCCCATGGACACACAGACATGCAAGTTGCAGCTGGAAAGC
TGGGGCTATGATGGAAATGATGTGGAGTTCACCTGGCTGAGAGGGAACGACTCTGTGCGT
GGACTGGAACACCTGCGGCTTGCTCAGTACACCATAGAGCGGTATTTCACCTTAGTCACC
AGATCGCAGCAGGAGACAGGAAATTACACTAGATTGGTCTTACAGTTTGAGCTTCGGAGG
AATGTTCTGTATTTCATTTTGGAAACCTACGTTCCTTCCACTTTCCTGGTGGTGTTGTCC
TGGGTTTCATTTTGGATCTCTCTCGATTCAGTCCCTGCAAGAACCTGCATTGGGGACAAC
AAAGGAAGTAGAAGAAGTCAGTATTACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9UN88" source="Swiss-Prot">
        <name>Gamma-aminobutyric acid receptor subunit theta</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.</specific-function>
        <gene-name>GABRQ</gene-name>
        <locus/>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>269-289
327-347
612-632</transmembrane-regions>
        <signal-regions>1-21</signal-regions>
        <theoretical-pi>5.76</theoretical-pi>
        <molecular-weight>72020.875</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:14454</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF189259</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7861736</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UN88</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GBRT_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GABA(A) receptor subunit theta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012499|Gamma-aminobutyric acid receptor subunit theta
MGIRGMLRAAVILLLIRTWLAEGNYPSPIPKFHFEFSSAVPEVVLNLFNCKNCANEAVVQ
KILDRVLSRYDVRLRPNFGGAPVPVRISIYVTSIEQISEMNMDYTITMFFHQTWKDSRLA
YYETTLNLTLDYRMHEKLWVPDCYFLNSKDAFVHDVTVENRVFQLHPDGTVRYGIRLTTT
AACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWDDNGNAIHMTEELHIPQFTFLGRTI
TSKEVYFYTGSYIRLILKFQVQREVNSYLVQVYWPTVLTTITSWISFWMNYDSSAARVTI
GLTSMLILTTIDSHLRDKLPNISCIKAIDIYILVCLFFVFLSLLEYVYINYLFYSRGPRR
QPRRHRRPRRVIARYRYQQVVVGNVQDGLINVEDGVSSLPITPAQAPLASPESLGSLTST
SEQAQLATSESLSPLTSLSGQAPLATGESLSDLPSTSEQARHSYGVRFNGFQADDSIFPT
EIRNRVEAHGHGVTHDHEDSNESLSSDERHGHGPSGKPMLHHGEKGVQEAGWDLDDNNDK
SDCLAIKEQFKCDTNSTWGLNDDELMAHGQEKDSSSESEDSCPPSPGCSFTEGFSFDLFN
PDYVPKVDKWSRFLFPLAFGLFNIVYWVYHMY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012500|Gamma-aminobutyric acid receptor subunit theta (GABRQ)
ATGGGCATCCGAGGCATGCTGCGAGCCGCAGTGATCCTGCTGCTCATCAGGACCTGGCTC
GCGGAGGGCAACTACCCCAGTCCCATCCCGAAATTCCACTTCGAGTTCTCCTCTGCTGTG
CCCGAAGTCGTCCTGAACCTCTTCAACTGCAAAAATTGTGCAAATGAAGCTGTGGTTCAA
AAGATTTTGGACAGGGTGCTGTCAAGATACGATGTCCGCCTGAGACCGAATTTTGGAGGT
GCCCCTGTGCCTGTGAGAATATCTATTTATGTCACGAGCATTGAACAGATCTCAGAAATG
AATATGGACTACACGATCACGATGTTTTTTCATCAGACTTGGAAAGATTCACGCTTAGCA
TACTATGAGACCACCCTGAACTTGACCCTGGACTATCGGATGCATGAGAAGTTGTGGGTC
CCTGACTGCTACTTTCTGAACAGCAAGGATGCTTTCGTGCATGATGTGACTGTGGAGAAT
CGCGTGTTTCAGCTTCACCCAGATGGAACGGTGCGGTACGGCATCCGACTCACCACTACA
GCAGCTTGTTCCCTGGATCTGCATAAATTCCCTATGGACAAGCAGGCCTGCAACCTGGTG
GTAGAGAGCTATGGTTACACGGTTGAAGACATCATATTATTCTGGGATGACAATGGGAAC
GCCATCCACATGACTGAGGAGCTGCATATCCCTCAGTTCACTTTCCTGGGAAGGACGATT
ACTAGCAAGGAGGTGTATTTCTACACAGGTTCCTACATACGCCTGATACTGAAGTTCCAG
GTTCAGAGGGAAGTTAACAGCTACCTTGTGCAAGTCTACTGGCCTACTGTCCTCACCACT
ATTACCTCTTGGATATCGTTTTGGATGAACTATGATTCCTCTGCAGCCAGGGTGACAATT
GGCTTAACTTCAATGCTCATCCTGACCACCATCGACTCACATCTGCGGGATAAGCTCCCC
AACATTTCCTGTATCAAGGCCATTGATATCTATATCCTCGTGTGCTTGTTCTTTGTGTTC
CTGTCCTTGCTGGAGTATGTCTACATCAACTATCTTTTCTACAGTCGAGGACCTCGGCGC
CAGCCTAGGCGACACAGGAGACCCCGAAGAGTCATTGCCCGCTACCGCTACCAGCAAGTG
GTGGTAGGAAACGTGCAGGATGGCCTGATTAACGTGGAAGACGGAGTCAGCTCTCTCCCC
ATCACCCCAGCGCAGGCCCCCCTGGCAAGCCCGGAAAGCCTCGGTTCTTTGACGTCCACC
TCCGAGCAGGCCCAGCTGGCCACCTCGGAAAGCCTCAGCCCACTCACTTCTCTCTCAGGC
CAGGCCCCCCTGGCCACTGGAGAAAGCCTGAGCGATCTCCCCTCCACCTCAGAGCAGGCC
CGGCACAGCTATGGTGTTCGCTTTAATGGTTTCCAGGCTGATGACAGTATTATTCCTACC
GAAATCCGCAACCGTGTCGAAGCCCATGGCCATGGTGTTACCCATGACCATGAAGATTCC
AATGAGAGCTTGAGCTCGGATGAGCGCCATGGCCATGGCCCCAGTGGGAAGCCCATGCTT
CACCATGGCGAGAAGGGTGTGCAAGAAGCAGGCTGGGACCTTGATGACAACAATGACAAG
AGCGACTGCCTTGCCATTAAGGAGCAATTCAAGTGTGATACTAACAGTACCTGGGGCCTT
AATGATGATGAGCTCATGGCCCATGGCCAAGAGAAGGACAGTAGCTCAGAGTCTGAGGAT
AGTTGCCCCCCAAGCCCTGGGTGCTCCTTCACTGAAGGGTTCTCCTTCGATCTCTTTAAT
CCTGACTACGTCCCAAAGGTCGACAAGTGGTCCCGGTTCCTCTTCCCTCTGGCCTTTGGG
TTGTTCAACATTGTTTACTGGGTATACCATATGTATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>chloride channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>GABA-A receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GABA-A receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotransmitter transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chloride transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>